Adakveo
Adakveo
ADAKVEO ® (crizanlizumab-tmca) is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients, aged 16 years and older, with sickle cell disease.
Administration Information
ADAKVEO is administered by IV infusion over a period of 30 minutes at Weeks 0 and 2, then every 4 weeks.
Induction period (week 0, 2, ) - Speak With Doctor About Details
Potential Side Effects
In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.
For a full list of potential side effects, please see the Important Safety Information and Medication Guide on the Zemaira website.
Helpful Resources
Patient Forms
Before you attend your first appointment at Omega Health, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices and Patient Rights and Responsibilities are for reference only. Please contact us if you have any questions!
Patient Consent Form
Print & Sign
HIPAA Privacy Authorization Form
Print & Sign
Notice of Privacy Practice
Read
Patient Rights and Responsibilities
Read
Appointment Lateness and Cancelation
Read
